📊 NMTC Key Takeaways
Is NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) a Good Investment?
NeuroOne Medical Technologies demonstrates strong revenue growth (+163.5% YoY) and maintains a healthy balance sheet with minimal debt, but the company is burning cash at an alarming rate (-$3.1M operating cash flow) with negative operating margins (-59%) and persistent unprofitability (-$1.4M net loss). The gross margin of 54.2% suggests product viability, yet operational efficiency deteriorates significantly once operating expenses are considered, indicating the growth is not yet translating to sustainable business operations.
NeuroOne shows strong top-line momentum with 163% YoY revenue growth and healthy 54% gross margins, supported by a clean, low-leverage balance sheet and robust liquidity. However, the business remains unprofitable with materially negative operating cash flow and free cash flow, indicating ongoing cash burn. The outlook hinges on achieving operating leverage and demonstrating a credible path to break-even without dilutive financing.
Why Buy NEUROONE MEDICAL TECHNOLOGIES Corp Stock? NMTC Key Strengths
- Strong revenue growth of 163.5% YoY demonstrates significant market traction
- Excellent liquidity position with 6.41x current ratio and $3.6M cash reserves
- Minimal debt burden with debt-to-equity of 0.01x and only $55.3K long-term debt
- Healthy gross margin of 54.2% indicates strong product pricing power and manufacturing efficiency
- Rapid revenue growth
- Healthy gross margin profile
- Strong liquidity and minimal debt
NMTC Stock Risks: NEUROONE MEDICAL TECHNOLOGIES Corp Investment Risks
- Severe cash burn of $3.1M in operating activities against only $2.9M revenue indicates unsustainable operations
- Negative operating margin of -59% and net margin of -49.7% show inability to control operating expenses relative to revenue
- Interest coverage ratio of -559.2x reflects lack of profitability to service obligations
- Free cash flow of -$3.2M means the company is consuming cash reserves; at current burn rate, cash runway is approximately 14 months
- Deteriorating profitability despite revenue growth suggests expansion is capital-inefficient
- Sustained negative free cash flow
- Unproven operating leverage to profitability
- Potential need for external capital/dilution
Key Metrics to Watch
- Quarterly operating cash flow trends and path to cash flow breakeven
- Operating margin improvement as the company scales revenue
- Cash burn rate and projected runway of remaining reserves
- Operating expense ratio relative to revenue growth
- Gross margin sustainability as manufacturing scales
- Insider trading activity trends indicating management confidence
- Operating margin to break-even
- Quarterly operating cash flow
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.41x current ratio provides a solid financial cushion.
NMTC Profit Margin, ROE & Profitability Analysis
NMTC vs Healthcare Sector: How NEUROONE MEDICAL TECHNOLOGIES Corp Compares
How NEUROONE MEDICAL TECHNOLOGIES Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NEUROONE MEDICAL TECHNOLOGIES Corp Stock Overvalued? NMTC Valuation Analysis 2026
Based on fundamental analysis, NEUROONE MEDICAL TECHNOLOGIES Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NEUROONE MEDICAL TECHNOLOGIES Corp Balance Sheet: NMTC Debt, Cash & Liquidity
NMTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NEUROONE MEDICAL TECHNOLOGIES Corp's revenue has grown significantly by 5,007% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
NMTC Revenue Growth, EPS Growth & YoY Performance
NMTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.9M | -$1.4M | $-0.03 |
| Q3 2025 | $825.8K | -$1.5M | $-0.03 |
| Q2 2025 | $1.4M | -$485.3K | $-0.02 |
| Q1 2025 | $977.6K | $1.8M | $0.06 |
| Q3 2024 | $629.9K | -$1.7M | $-0.10 |
| Q2 2024 | $466.2K | -$1.7M | $-0.11 |
| Q1 2024 | $114.6K | -$1.7M | $-0.11 |
| Q3 2023 | $32.0K | -$1.7M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NEUROONE MEDICAL TECHNOLOGIES Corp Dividends, Buybacks & Capital Allocation
NMTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NMTC
What is the AI rating for NMTC?
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NMTC's key strengths?
Claude: Strong revenue growth of 163.5% YoY demonstrates significant market traction. Excellent liquidity position with 6.41x current ratio and $3.6M cash reserves. ChatGPT: Rapid revenue growth. Healthy gross margin profile.
What are the risks of investing in NMTC?
Claude: Severe cash burn of $3.1M in operating activities against only $2.9M revenue indicates unsustainable operations. Negative operating margin of -59% and net margin of -49.7% show inability to control operating expenses relative to revenue. ChatGPT: Sustained negative free cash flow. Unproven operating leverage to profitability.
What is NMTC's revenue and growth?
NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $2.9M.
Does NMTC pay dividends?
NEUROONE MEDICAL TECHNOLOGIES Corp does not currently pay dividends.
Where can I find NMTC SEC filings?
Official SEC filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NMTC's EPS?
NEUROONE MEDICAL TECHNOLOGIES Corp has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NMTC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NEUROONE MEDICAL TECHNOLOGIES Corp has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NMTC stock overvalued or undervalued?
Valuation metrics for NMTC: ROE of -22.5% (sector avg: 15%), net margin of -49.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NMTC stock in 2026?
Our dual AI analysis gives NEUROONE MEDICAL TECHNOLOGIES Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NMTC's free cash flow?
NEUROONE MEDICAL TECHNOLOGIES Corp's operating cash flow is $-3.1M, with capital expenditures of $40.8K. FCF margin is -109.1%.
How does NMTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -49.7% (avg: 12%), ROE -22.5% (avg: 15%), current ratio 6.41 (avg: 2).